Mitochondrial Biogenesis & Uncoupling — References

Navigation

• Parent Topic: Mitochondrial Biogenesis & Uncoupling
• Reference Hub: 04 - Longevity & Environment References MOC

---

Primary Literature Dossier

1. Robinson et al. (2017) — High-Intensity Interval Training Reverses Mitochondrial Decline in Aging Human Skeletal Muscle

• Citation: Robinson MM, Dasari S, Konopka AR, Johnson ML, Manjunatha S, Esponda RR, Carter RE, Lanza IR, Nair KS. Enhanced Protein Translation Underlies Improved Metabolic and Physical Adaptations to Different Exercise Training Modes in Young and Old Humans. Cell Metabolism. 2017 Mar 7;25(3):581-592.
• Identifiers: PMID: 28273480 (PubMed · Europe PMC) | DOI: 10.1016/j.cmet.2017.02.009 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Randomized controlled physiological trial ($n=72$ sedentary young [18–30 yrs] and older [65–80 yrs] men and women assigned for 12 weeks to High-Intensity Interval Training [HIIT], Resistance Training, or Combined Training, with ${\text{D}}_2\text{O}$ heavy-water labeling, muscle biopsies, proteomics, and RNA-seq).
• Key Quantitative Outcomes:
  • In older adults, 12 weeks of HIIT ($4\times 4\text{ min}$ intervals at $>90\%{\text{ VO}}_2\text{ peak}$) increased mitochondrial respiration capacity by 49% in young and 69% in older adults, alongside a 17% increase in ${\text{VO}}_2\text{ peak}$ and significant improvement in insulin sensitivity.
  • HIIT upregulated 274 age-sensitive proteins in older skeletal muscle, specifically reversing age-related declines in Complex I–V OXPHOS subunits and mitochondrial ribosomal translation machinery via $\text{PGC-1}\alpha$ and $\text{TFAM}$.

2. Harris et al. (2013) — Dietary Pyrroloquinoline Quinone (PQQ) Alters Mitochondrial-Related Metabolism and Inflammation in Humans

• Citation: Harris CB, Chowanadisai W, Mishchuk DO, Satre MA, Slupsky CM, Rucker RB. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. The Journal of Nutritional Biochemistry. 2013 Dec;24(12):2076-2084.
• Identifiers: PMID: 24231099 (PubMed · Europe PMC) | DOI: 10.1016/j.jnutbio.2013.07.008 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Two-phase human clinical intervention ($n=20$ adult men and women; single dose $0.2\text{ mg/kg}$ and continuous daily dosing $0.3\text{ mg/kg/day}$ [$\sim 20\text{ mg/day}$] with ${}^1\text{H-NMR}$ urinary metabolomics and plasma cytokine/lipid peroxidation profiling).
• Key Quantitative Outcomes:
  • Plasma C-reactive protein (CRP) and interleukin-6 ($\text{IL-6}$) decreased by 35–45% ($p<0.05$) within 3 days of PQQ supplementation, accompanied by a significant drop in plasma malondialdehyde (TBARS lipid peroxidation).
  • Urinary ${}^1\text{H-NMR}$ metabolomics showed a coordinated reduction in excreted TCA cycle intermediates (citrate, fumarate, succinate, 2-oxoglutarate) and blood lactate:pyruvate ratio, demonstrating enhanced mitochondrial oxidative flux.

3. Karaa et al. (2018) / Thompson et al. (2024) — Elamipretide (SS-31) Cardiolipin Stabilization in Human Mitochondrial Disease

• Citation: Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018 Apr 3;90(14):e1212-e1221.
• Identifiers: PMID: 29500292 (PubMed · Europe PMC) | DOI: 10.1212/WNL.0000000000005255 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Randomized, double-blind, placebo-controlled dose-escalation trial ($n=36$ patients with genetically confirmed primary mitochondrial myopathy treated with $0.01,0.1,$ or $0.25\text{ mg/kg/h}$ IV elamipretide for 5 days).
• Key Quantitative Outcomes:
  • Highest-dose elamipretide ($0.25\text{ mg/kg/h}$) produced an immediate dose-dependent $+64.5\text{ m}$ improvement in 6-minute walk test (6MWT) distance ($p=0.014$) compared to $+20.4\text{ m}$ in placebo, by directly stabilizing inner mitochondrial membrane cardiolipin and respiratory supercomplexes without requiring de novo protein synthesis.

4. Brand (2000) — Uncoupling to Survive: Proton Conductance and Longevity

• Citation: Brand MD. Uncoupling to survive? The role of mitochondrial inefficiency in ageing. Experimental Gerontology. 2000 Jul;35(4):811-820.
• Identifiers: PMID: 11053672 (PubMed · Europe PMC) | DOI: 10.1016/s0531-5565(00)00135-2 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Foundational bioenergetic and comparative physiology synthesis across mammalian species and isolated mitochondria.
• Key Quantitative Outcomes:
  • Quantified that basal and inducible mitochondrial proton leak (mediated by $\text{ANT}$ and $\text{UCP1–3}$) consumes 20–25% of whole-body resting oxygen uptake in mammals.
  • Demonstrated that because mitochondrial superoxide production at Complex I and III is steeply exponential at high membrane potentials ($\Delta {\Psi }_m>165\text{ mV}$), mild uncoupling that lowers $\Delta {\Psi }_m$ by just $5\text{–}10\text{ mV}$ reduces free radical generation by 50–70%, preserving $\text{mtDNA}$ and membrane lipids across the lifespan.